Induction of robust type-1 CD8(+) T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC

PURPOSE: WHO grade II low-grade gliomas (LGGs) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Okada, Hideho, Butterfield, Lisa H., Hamilton, Ronald L., Hoji, Aki, Sakaki, Masashi, Ahn, Brian J., Kohanbash, Gary, Drappatz, Jan, Engh, Johnathan, Amankulor, Nduka, Lively, Mark O., Chan, Michael D., Salazar, Andres M., Shaw, Edward G., Potter, Douglas M., Lieberman, Frank S.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297523/
https://ncbi.nlm.nih.gov/pubmed/25424847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1790
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares